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Background: In this open-label phase I study, the  maximum-tolerated 
dose of cetuximab with concurrent chemoradiotherapy (C-CRT) in 
stage III non–small-cell lung cancer together with individualized, 
isotoxic accelerated radiotherapy (RT) was investigated.
Methods: Patients with stage III non–small-cell lung cancer, World 
Health Organization performance status 0–1, forced expiratory vol-
ume in 1 second more than 50%, carbon monoxide diffusing capacity 
more than 50%, weight loss less than 10%, and no severe comorbidity 
were enrolled. Patients without progression after one to two cycles of 
gemcitabine–carboplatin were included and treated with cetuximab 
400 mg/kg d7 and 250 mg/kg weekly together with RT and cisplatin 
(50 mg/m2 d1, 8; 40 mg/m2 d22)–vinorelbine for 5 weeks. Vinorelbine 
was escalated in three steps; (1) 10 mg/m2 d1, 8 and 8 mg/m2 d22, 29; 
(2) 20 mg/m2 d1, 8 and 8 mg/m2 d22, 29; (3) 20 mg/m2 d1, 8; 15 mg/
m2 d22, 29. An individualized prescribed RT dose based on normal 
tissue dose constraints was applied (e.g., mean lung dose 19 Gy). The 
primary endpoint was the maximum-tolerated dose 3 months after 
the end of C-CRT; secondary endpoints were toxicity and metabolic 
response as assessed by positron emission tomography.
Results: Between September 2007 and October 2010, 25 patients 
(12 men, 13 women, mean age 59 years) were included. The mean 
RT dose was 62 ± 6.6 Gy. The vinorelbine dose could be escalated to 
dose level 3. Twelve of 25 patients experienced greater than or equal 
to grade 3 toxicity (esophagitis 3, rash 1, diarrhea 1, cough 1, dys-
pnea 1, vomiting 1, and pulmonary embolism 1). No dose-limiting 
toxicities were observed. One patient with a complete pathological 
response in dose level 3 developed a fatal hemoptysis 4 months after 
RT. Metabolic remissions were observed in 19 of 22 patients.
Conclusion: C-CRT with cetuximab and cisplatin–vinorelbine is safe 
to deliver at full dose. The recommended phase II dose is therefore 
cetuximab 400 mg/m2 d7 and 250 mg/m2 weekly, cisplatin 50 mg/m2 
d1, 8; 40 mg/m2 d22 and vinorelbine 20 mg/m2 d1, 8; 15 mg/m2 d22, 
29 for 5 weeks together with RT.
Key Words: NSCLC, Concurrent chemoradiotherapy, Cetuximab, 
Phase I.
(J Thorac Oncol. 2014;9: 710–716)
Approximately 30% of patients with non–small-cell lung cancer (NSCLC) present with locally advanced dis-
ease (stage III), for which concurrent chemoradiotherapy 
(C-CTRT) is mostly the treatment of choice.1,2 Even recent 
series only show a 5-year survival of approximately 25%.3 
Local progression occurs in more than 40% of patients and 
most develop distant metastases.4 Cisplatin has been the back-
bone in most series of C-CTRT, with an additional drug such 
as etoposide or vinorelbine, although cisplatin alone leads to 
similar outcomes as doublet chemotherapy.5,6
As there is much room for improvement, investigators 
have combined chemotherapy with cetuximab, a monoclo-
nal antibody against the epidermal growth factor receptor.7 
Preclinical studies indicated a strong radiosensitizing effect of 
cetuximab, which was supported by the improved survival of 
patients with locally advanced squamous cancer of the head 
and neck treated with cetuximab and radiation therapy com-
pared with radiotherapy (RT) alone.8,9 Laboratory studies have 
also shown that the tumor uptake of cetuximab can vary sig-
nificantly.10,11 Local tumor control of NSCLC shows a dose–
response relationship, with higher doses of RT delivered in a 
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short overall treatment time leading to higher overall survival 
(OS) rates.12 Isotoxic accelerated radiotherapy (INDAR) is a 
way to deliver to each individual patient the highest dose of 
RT in the shortest possible treatment time without increasing 
toxicity.13,14 As the variability of the radiation dose between 
patients to the lungs is lower with INDAR than with a standard 
approach where the dose to the tumor is kept constant but the 
radiation dose to the organs at risk differs widely, this strategy 
is particularly appealing for phase I trials in which the primary 
endpoint is typically toxicity. The derived estimations of the 
maximum-tolerated dose (MTD) with INDAR in combination 
with novel drugs will be more reliable than if the dose–volume 
parameters to the normal tissues would differ significantly 
between enrolled patients. Furthermore, phase I trials of drugs 
with radiation have specific features previously described.15
As lowering the cetuximab dose would not be logical 
for biological and toxicity reasons and lowering the dose of 
radiation would be methodologically incorrect,15 we decided to 
combine INDAR with the standard dose of cisplatin and cetux-
imab with escalating doses of vinorelbine. Here, we report the 
long-term data of a phase I trial aiming to determine the rec-
ommended phase 2 dose of concurrent cisplatin–vinorelbine–
cetuximab and individualized INDAR in stage III NSCLC.
PATIENTS AND METHODS
The study was performed in two hospitals in The 
Netherlands. For RT, patients were referred to a single institute 
(MAASTRO Clinic). The study was designed as an  open-label 
phase I study.
Inclusion criteria were as follows: pathologically proven 
NSCLC, stage III disease, World Health Organization (WHO) 
performance status 0–1, forced expiratory volume in 1 second 
more than 50%, carbon monoxide diffusing capacity more 
than 50%, weight loss less than 10%, no severe cardiac dis-
ease, creatinine clearance (Cockcroft) more than 60 ml/min. 
Patients with mixed histology, malignant pleural, or pericar-
dial effusion were excluded.
The study was approved by the local medical ethics 
committees, and all patients signed informed consent before 
entering the study. The study was registered at clinicaltrials.
gov (NCT00522886).
Treatment
Treatment scheme and dose escalation are displayed 
in Figure 1. Patients were treated with two cycles of gem-
citabine (1250 mg/m2 d1, 8) and carboplatin (area under the 
curve 5 d1 every 3 weeks). In 2010, however, the study was 
amended after the publication of Cancer and Leukemia Group 
B (CALGB) 30105, which showed no benefit of induction 
chemotherapy.16 For practical reasons, a single cycle of induc-
tion carboplatin–gemcitabine was still administered before 
the start of C-CRT. Patients without progression after gem-
citabine/carboplatin were included in the phase I part and 
treated with cetuximab 400 mg/m2 d7 (1 week before the start 
of RT) and 250 mg/m2 weekly thereafter together with RT and 
cisplatin (50 mg/m2 d1, 8; and 40 mg/m2 d22) plus vinorelbine 
for 5 weeks. Vinorelbine was escalated in three steps—step 
1: 10 mg/m2 d1, 8 and 8 mg/m2 d22, 29; step 2: 20 mg/m2 d1, 
8 and 8 mg/m2 d22, 29; step 3: 20 mg/m2 d1, 8 and 15 mg/m2 
d22, 29. The radiation dose was 45 Gy, given in 30 twice daily 
fractions of 1.5 Gy, immediately followed by once-daily frac-
tions of 2 Gy until a mean lung dose of 19 Gy or another nor-
mal tissue constraint, as previously described,13,14 was reached. 
The maximal allowed dose was 69 Gy in 6 weeks.
RT planning was done as previously described.13,14 
In short, a positron emission tomography (PET)-computed 
tomography (CT), with intravenous contrast for the CT, was 
used for RT planning. The gross tumor volume (GTV) of the 
primary tumor was delineated on the CT with lung window, 
with the lymph nodes on mediastinal settings. Only fluorode-
oxyglucose (FDG)-avid nodes or those proven to be positive 
on endoscopic examination with biopsy were included in the 
nodal GTV. The clinical target volume was defined as the GTV 
with a margin of 5 mm, edited according to organs at risk (e.g., 
the bones). The planning target volume was made by expand-
ing the clinical target volume with a margin of an average 
10 mm, according to the movement of the tumor and the setup 
error. The organs at risk (lungs, esophagus, spinal cord, and 
heart) were contoured on each slide throughout the thorax.
Calculation of the dose distribution was done with a 
CMS (XiO) treatment planning system using a superposition–
convolution algorithm, according to International Commission 
on Radiation Units (ICRU) 50 standards. Portal imaging and 
exit dosimetry were used for quality control during treatment.
Toxicity
Toxicity was scored from baseline until 3 months after 
the last day of RT, according to the Common Toxicity Criteria 
for Adverse Events version 3.0. As clinical dyspnea and pneu-
monitis overlap in Common Toxicity Criteria for Adverse 
Events version 3.0, it was decided to report dyspnea only.
FIGURE 1.  Treatment and dose escalation scheme. 
#Vinorelbine dose escalation. Step 1: 10 mg/m2 d1, 8 and 
8 mg/m2 d22, 29; step 2: 20 mg/m2 d1, 8 and 8 mg/m2 d22, 
29; step 3: 20 mg/m2 d1, 8 and 15 mg/m2 d22, 29.
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Endpoints
The primary endpoint of the study was the MTD. 
Secondary endpoints were toxicity and metabolic response 
as assessed by FDG-PET 3 months after C-CTRT, according 
to the Positron Emission Tomography Response Criteria in 
Solid Tumors of the European Organization for Research and 
Treatment of Cancer.17,18
Study Design
Patients were followed for toxicity until 3 months after 
the last day of C-CTRT: weekly during C-CTRT and every 
4 weeks thereafter till 3 months after C-CTRT. Every cohort 
consisted of six patients: when six patients were entered in a 
certain cohort, the study was “on hold” until all patients had 
been followed for 3 months after RT and no MTD-defining 
toxicity observed in the cohort. MTD was defined as: greater 
than or equal to two of six patients had greater than or equal 
to grade 3 pneumonitis, diarrhea, liver, or renal toxicity or 
greater than or equal to three of six patients had greater than 
or equal to grade 3 esophagitis. If there was no MTD in a 
cohort, then if one of six patients in the cohort had developed 
grade 4 skin or neurological toxicity or grade 5 hematological 
toxicity, the dose level was extended with six patients (Fig. 2). 
Patients were included in the next dose level when all patients 
in a given dose level had been followed for 3 months and 
MTD was not reached. Safety data were analyzed by an inde-
pendent safety data monitoring board. OS was defined as the 
time from study inclusion till death. Progression-free survival 
(PFS) was defined as time from inclusion till progression or 
death. Patients were censored at date of last follow-up.
RESULTS
Patient Characteristics
Between September 2007 and October 2010, 27 patients 
were included in the trial: six in dose level 1, six in dose level 2, 
and 15 in dose level 3. Six extra patients were enrolled in dose 
level 3, at the request of the independent safety monitoring 
board, of whom three were replaced (two patients did not enter 
the phase I part of the study because of toxicity of the induction 
treatment and disease progression after induction treatment; 
one patient withdrew consent and stopped treated after one 
cycle of C-CRT without an MTD-defining toxicity). Finally, 
25 of 27 enrolled in the phase I study and were included in the 
safety analysis and 24 of 27 in the survival analysis. The patient 
characteristics of these 25 patients (12 men and 13 women, 
mean age 59 years) are described in Table 1. As the study was 
amended in January 2010, patients in cohort 3 (extension) 
received one course instead of two courses of induction treat-
ment. This amendment was submitted because at the time of 
inclusion of the extra patients in the level 3 cohort the standard 
care of patients with stage III NSCLC had changed; it had been 
shown that induction chemotherapy is not additive.
Dose Intensity and Toxicity
All assessable patients received the planned number 
of courses of chemotherapy. The first 18 patients, six in each 
cohort, received two courses of induction treatment with car-
boplatin and gemcitabine; dose reduction or delay of the sec-
ond cycle was necessary in five of 18 patients (two dose level 
1 and three in dose level 2), all because of hematological tox-
icity. In the concurrent phase of the treatment in dose level 1, a 
dose reduction and a delay of treatment were necessary in one 
patient because of renal toxicity; in dose level 2, in one patient 
the dose of chemotherapy was reduced because of hemato-
logical toxicity; in dose level 3, chemotherapy was delayed in 
five of 12 assessable patients: one because of logistic reasons, 
one because of hematological toxicity, one because of patient 
decision, one because of infection, and one unknown (Table 2). 
As stated before in this cohort, one patient stopped prema-
turely; she withdrew consent and stopped treatment because 
of psychological reasons.
FIGURE 2.  Dose escalation scheme.
TABLE 1.  Patients Characteristics
Total Step 1 Step 2 Step 3
n 25 6 6 13
Age (yr), mean (range) 59 (45–72) 60 (48–67) 66 (52–71) 58 (45–72)
Sex (male/female) 12/13 5/1 4/2 3/10
WHO PS
  0 18 4 8
  1 7 2 6 5
Histology
  Adenocarcinoma 8 0 3 5
  Squamous 6 2 0 4
  Large cell 2 0 1 1
  Large cell NOS 9 4 2 3
EGFR mutation
  Positive 0 0 0 0
  Negative 6 0 1 5
  Unknown 19 6 5 8
KRAS mutation
  Positive 3 0 1 2
  Negative 3 0 0 3
  Unknown 19 6 5 8
EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma; NOS, not 
otherwise specified; PS, performance status; WHO, World Health Organization.
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Median overall treatment time, defined as first day of 
induction chemotherapy till last day of RT was 75 days (range 
24–93 days); for the 18 patients with two cycles of induction 
treatment, the median overall treatment time was 76 days and 
for the six patients with one cycle of induction treatment, 57 
days. Median total radiation dose was 65 Gy (range 9–69 
Gy). Median lung dose was 17 Gy (range 5.0–20.2 Gy), and 
median esophagus dose was 25.6 Gy (range 14.4–37.8 Gy).
The dose could be escalated to dose level 3. No 
 dose-limiting toxicities were observed. Twelve of 25 
patients experienced greater than or equal to grade 3 tox-
icity (fatigue, esophagitis, skin toxicity, diarrhea, cough, 
dyspnea, vomiting, and pulmonary embolism; Table 3). 
Dose-limiting toxicity (DLT) was not reached. The most 
frequent toxicity was skin rash.
One patient in dose level 3 developed a fatal hemop-
tysis 4 months after RT. This was a patient with a complete 
metabolic response at 3 months. Necropsy was performed. 
No cancer was found. Although this event occurred after the 
defined MTD period (3 months after C-CRT), it was decided 
after discussion with the independent safety monitoring board 
to enroll six extra patients at dose level 3. In this additional 
cohort, two patients did not enter the phase I trial and one 
patient stopped treatment without a DLT before the MTD 
period of 3 months after C-CRT. This patient was however 
included in the analysis for toxicity and survival.
The recommended phase II dose is therefore cetuximab 
400 mg/m2 d7 and 250 mg/m2 weekly, cisplatin 50 mg/m2 d1, 
8; 40 mg/m2 d22 and vinorelbine 20 mg/m2 d1, 8; 15 mg/m2 
d22, 29 for 5 weeks together with RT.
The database was closed in October 2012 when the last 
patient had been followed up for 2 years. Median OS was 21.0 
months (95% confidence interval 19.0–22.8 months), and 
2-year survival rate was 42%. Median PFS was 14.8 months, 
95% confidence interval 5.5 to 24.0 months; 2-year PFS rate 
was 40% (Fig. 3).
FDG-PET scans 3 months after C-CRT were available 
for 22 patients. According to Positron Emission Tomography 
Response Criteria in Solid Tumors, eight patients had a com-
plete metabolic response, 11 a partial response, and three 
patients a progressive disease.
DISCUSSION
Several attempts have been made to improve the outcome 
of stage III NSCLC patients. Strong preclinical data and other 
early clinical trials in NSCLC support the use of cetuximab 
delivered concurrently with chemotherapy and RT.14 At the 
time of developing this protocol, no data were available about 
the combination of cetuximab with cisplatin and vinorelbine. 
Moreover, we chose to use INDAR as a way to deliver to each 
individual patient the highest dose of RT in the shortest pos-
sible treatment time without increasing toxicity.13,14 As this is 
an “equitoxic” approach, the variability of the radiation dose 
between patients to the lungs is lower with INDAR than with a 
standard strategy where the dose to the tumor is kept constant 
but the radiation dose to the organs at risk differs widely. The 
derived estimations with INDAR of the MTD of INDAR in 
combination with novel drugs will be more reliable than if the 
dose–volume parameters to the normal tissues would differ 
significantly between enrolled patients.
Because cisplatin is the backbone of C-CRT schedules 
and lowering the cetuximab dose did not seem to be necessary 
in view of its low toxicity, we designed a trial in which vinorel-
bine was escalated. The aim of this study was to establish the 
MTD of C-CRT with cetuximab–vinorelbine–cisplatin.
The MTD was not reached, and the dose could be esca-
lated to the full dose of vinorelbine. The MTD observation 
period was 3 months after C-CTRT, implying that between the 
different dose levels during a period of 6 months (treatment 
period of last patient enrolled and 3 months follow-up) no 
patients were enrolled in the study that is common in phase 1 
trials involving RT.15 This, together with the decision to enroll 
six additional patients in dose level 3 because of a grade 4 
hemoptysis 4 months after the end of treatment, prolonged 
the duration of this study considerably. At the time, the study 
was designed using gemcitabine–carboplatin as induction 
chemotherapy was common in our region. Evidence about 
induction treatment changed and resulted in an amendment 
to omit the two cycles of induction chemotherapy and to use 
for practical reasons only a single cycle of induction chemo-
therapy. We believe, however, that the amendment has not 
influenced the outcome of the study, as in the later cohorts 
(with only one cycle of induction treatment) certainly no less 
toxicity was observed.
In two other studies, the addition of cetuximab to 
C-CRT in locally advanced NSCLC was investigated.19,20 In 
the CALGB trial 30407, carboplatin (AUC6)–pemetrexed 
500 mg/m2 was studied with or without the addition of cetux-
imab.19 In this randomized phase II study, systemic doses of 
chemotherapy and cetuximab were used for four cycles and 
four additional cycles of pemetrexed monotherapy, starting 
RT on day 1 of the chemotherapy. The main toxicity in the 
CALBG study was grade 4 thrombocytopenia, requiring dose 
reduction of carboplatin to AUC5 after 19 patients had been 
enrolled. No difference in toxicity was observed between the 
arms with and without cetuximab. Although the primary end-
point (OS at 18 months) was reached in this study, the differ-
ence between the arms was not significant (58% versus 54%).
The median failure-free survival was 12.6 versus 12.3 months.
The RTOG 0324 is a single-arm phase II study with 
the standard RTOG scheme of weekly carboplatin AUC2 and 
paclitaxel 45 mg/m2 for 6 weeks concurrent with the RT fol-
lowed by two cycles of consolidation chemotherapy with car-
boplatin AUC6 and paclitaxel 200 mg/m2. Weekly cetuximab 
TABLE 2.  Dose Reductions and Delays
Dose Level
1 2 3
n = 6 n = 6 n = 13
Induction treatment
  Delay 1 2 1
  Reduction 2 1 0
Concurrent
  Delay 1 1 5
  Reduction 1 0 0
714 Copyright © 2014 by the International Association for the Study of Lung Cancer
Dingemans et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 5, May 2014
TABLE 3.  Treatment-Related Toxicity CTCAE 3.0 More Than Grade 2
CTCAE 3.0 Grades
Step 1 Step 2 Step 3
All 3–4 All 3–4 All 3–4
n 6 6 13
Hematological
  Hemoglobin 4
  Thrombocytes 4 1 3
  Leukopenia 1 2 1 3 3
Constitutional
  Allergy 2
  Alopecia 5 1 4
  Blurred vision 1
  Cramps 1
  Dizziness 1
  Edema 1 1
  Fatigue 5 1 4 1 11 2
  Fever 1 1 2
  Hoarseness 1
  Infection 1 1 2
  Headache 3 2 2
  Hiccup 1
  Neurosensory 3 2
  Pain 1 6 1
  Ototoxicity 1
Gastrointestinal
  Anorexia 1
  Dysphagia/esophagitis 4 3 1 9 3
  Dyspepsia 1 2
  Diarrhea 1 1 4
  Nausea/vomiting 1 1 1 6 1
  Constipation 2 1 1 3 1
  Dehydration 1 1 1
  Liver function tests 1
  Loss of appetite 2
  Esophagus stenosis 1 1
  Taste alteration 1 1 2
  Stomatitis 1 4 1
  Weight loss 2 1
Dermatological
  Dermatitis 1
  Dry skin 4
  Itch 1 2
  Petechial 1
  Rash 5 5 12 1
  Burn
  Paronychia 2 1
  Rhagae 1 2
  Skin burn 1 1
Laboratory
  Creatinine 1 1 1
  Electrolyte disturbance
  Hypocalcemia 1 1
  Hypokalemia 1 1
  Hypomagnesemia 1 1
Respiratory
  Dyspnea 1 2
  Cough 1 1
CTCAE, Common Toxicity Criteria for Adverse Events.
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was added to the standard treatment. The primary endpoint 
was safety and compliance. In the 87 assessable patients, 
median OS was 22.7 months, which is longer than historical 
data from RTOG. Toxicity was mainly hematologic, with 20% 
grade 4 toxicities. Only 8% grade 3 esophagitis was reported. 
Esophagitis grade 3 or more in our study was 16% and com-
parable with data from other studies.
Toxicity in our series was in line with published tri-
als and our own experience,21–24 despite the administration 
of cetuximab in addition to cisplatin and vinorelbine and the 
delivery of intensified, high-dose RT. Severe radiation der-
matitis associated with concurrent cetuximab treatment, as 
was seen in patients with head and neck cancer,25 was not 
a major problem in our study with only one patient hav-
ing grade 3 rash. Severe neutropenia seems more frequent 
in cetuximab-treated patients according to a systematic 
review,26 most frequently in colorectal cancer and NSCLC. 
In our study, four of 25 patients (16%) experienced a grade 
3 neutropenia. In the CALBG 30407, no increase in febrile 
neutropenia was observed in the arm with cetuximab (8% 
versus 6%).19 In the RTOG 0324 study, with carboplatin and 
paclitaxel as backbone, 20% grade 4 hematological toxicities 
were observed.20 Surprisingly, we did not see patients with 
severe dyspnea indicating  radiation-induced pneumonitis in 
our study. Only three patients had dyspnea, one in dose level 
1 and two in dose level 3, all grade 1 to 2. This can be because 
of the short period of toxicity reporting in our phase I study 
(till 3 months after C-CRT) and the relatively small group of 
patients. Only one patient presented with hemoptysis, but in 
this case it was a very severe, fatal event in a patient with a 
complete pathological response. This patient had a very large 
(T4) adenocarcinoma in the right upper lobe with invasion 
of the mediastinum and congruent with lymph nodes 4R and 
7, with a good response after C-CRT. On CT, no cavitation 
was visible; however, pathological postmortem examination 
showed necrosis in the right upper lung in close relation with 
the vena cava superior and showed aspergillus infection in the 
necrotic tissue. In none of the other patients, hemoptysis was 
reported in the follow-up.
Despite a high rate of metabolic responses on 
 FDG-PET-CT scan 3 months after C-CRT, the OS was less 
than in previous trials and also inferior to our own series with 
concurrent INDAR and cisplatin–vinorelbine.10 Although we 
cannot rule out an interaction between cetuximab and other 
drugs, patient selection, the decreased vinorelbine dose in part 
of the patients, and the low number of patients may be reasons 
for the lower than expected OS in this phase I study that was 
not designed for OS assessment. Two recently published stud-
ies on the use cetuximab together with C-CRT did not show 
improvement in OS.27,28 Both these studies used a different 
chemotherapy and radiation schedule, being low-dose daily 
cisplatin with 66 Gy in 24 once-daily fractions and weekly 
carboplatin and paclitaxel with 60 Gy or 74 Gy in 2-Gy frac-
tions (RTOG0167), respectively. The combination of concur-
rent chemotherapy and RT with cetuximab is thus not useful 
in unselected patients.
Recently, it has been shown that high EGFR expression 
could be used as a biomarker to predict outcome in NSCLC 
patients treated with cisplatin–vinorelbine and cetuximab in 
the FLEX trial.7 Unfortunately, in our study, histological biop-
sies were not mandatory and a retrospective survey showed 
that not enough tumor material was available to do this analy-
sis. Furthermore, in a recently published study in the subgroup 
of patients with available material for EGFR testing, patients 
who had H-score more than 200 did not have better outcome 
when treated with cetuximab and C-CRT.27
There is still much room for improvement of treatment 
in stage III with C-CRT as the 5-year survival rates seems 
to stuck approximately 25%. Neither induction nor consoli-
dation chemotherapy have shown better outcomes.29,30 Both 
improvement of local control by more sophisticated RT31 and 
prevention of metastasis by systemic therapy are important. 
As the addition of cetuximab to intensified, accelerated RT 
and cisplatin–vinorelbine did not show DLT, this strategy, 
FIGURE 3. A, Overall survival; (B) progression-free survival.
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possibly strengthened by EGFR imaging or specific molecular 
markers, may be further pursued. The concept of using an iso-
toxic RT scheme to decrease the variability in toxicity due to 
dose–volume effects in phase I trials was shown to be practi-
cally feasible.
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